News | May 27, 2025
Akums reports Q4 FY25 with 12.4% revenue growth
Akums invested Rs. 272 crore in capital expenditure during FY25
Akums invested Rs. 272 crore in capital expenditure during FY25
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Allopurinol is used to prevent or lower high uric acid levels in the blood
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Subscribe To Our Newsletter & Stay Updated
